Showing results (51-60 of 108) with videos related to
Sort By:
Pageof 11
The Clinical Respiratory Journal|December 27, 2018
Small cell lung cancer in the young: Characteristics, diagnosis and outcome dataShiyu Jiang, Xuezhi Hao, Junling Li, et al.Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|June 4, 2019
Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatmentHaiyan Xu, Di Ma, Guangjian Yang, et al.Thoracic Cancer|September 7, 2021
Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinomaShouzheng Wang, Tongji Xie, Xuezhi Hao, et al.Journal of Cancer Research and Clinical Oncology|May 10, 2020
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomesYuxin Mu, Xuezhi Hao, Puyuan Xing, et al.Thoracic Cancer|January 22, 2025
Impact of EML4-ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non-small Cell Lung CancerZihua Zou, Lige Wu, Xuezhi Hao, et al.BMC Cancer|November 20, 2024
Efficacy and safety of RET-TKI in advanced RET-rearranged non-small cell lung cancer in China: a real-world retrospective chart reviewSiyu Lei, Linyan Tian, Lu Yang, et al.Thoracic Cancer|September 22, 2021
Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutationsTeng Li, Shouzheng Wang, Jianming Ying, et al.Cell Death & Disease|November 23, 2020
Long noncoding RNA HEIH depletion depresses esophageal carcinoma cell progression by upregulating microRNA-185 and downregulating KLK5Bing Wang, Xuezhi Hao, Xingkai Li, et al.Cancer Management and Research|March 8, 2022
Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese PatientsZiyi Xu, Xuezhi Hao, Qi Wang, et al.Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|September 17, 2013
[A retrospective study of the efficacy and toxicity of irinotecan in combination with nedaplatin versus irinotecan in combination with cisplatin as salvage treatment in refractory or relapsed small cell lung cancer]Shufei Yu, Yan Wang, Xingsheng Hu, et al.Pageof 11